

Divyanshu Dubey

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/892901/publications.pdf>

Version: 2024-02-01

75
papers

4,408
citations

159585

30
h-index

118850

62
g-index

75
all docs

75
docs citations

75
times ranked

3032
citing authors

#	ARTICLE	IF	CITATIONS
1	Autoimmune encephalitis epidemiology and a comparison to infectious encephalitis. <i>Annals of Neurology</i> , 2018, 83, 166-177.	5.3	479
2	Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2021, 8, .	6.0	313
3	Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders. <i>JAMA Neurology</i> , 2018, 75, 1355.	9.0	286
4	Clinical, Radiologic, and Prognostic Features of Myelitis Associated With Myelin Oligodendrocyte Glycoprotein Autoantibody. <i>JAMA Neurology</i> , 2019, 76, 301.	9.0	243
5	Expanded phenotypes and outcomes among 256 <scp>LGI</scp>1/<scp>CASPR</scp>2-â€‹<scp>I</scp>g<scp>G</scp>-positive patients. <i>Annals of Neurology</i> , 2017, 82, 79-92.	5.3	242
6	Kelch-like Protein 11 Antibodies in Seminoma-Associated Paraneoplastic Encephalitis. <i>New England Journal of Medicine</i> , 2019, 381, 47-54.	27.0	169
7	Diagnostic criteria for chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids (CLIPPERS). <i>Brain</i> , 2017, 140, 2415-2425.	7.6	158
8	Steroid-sparing maintenance immunotherapy for MOG-IgG associated disorder. <i>Neurology</i> , 2020, 95, e111-e120.	1.1	140
9	Severe Neurological Toxicity of Immune Checkpoint Inhibitors: Growing Spectrum. <i>Annals of Neurology</i> , 2020, 87, 659-669.	5.3	137
10	Autoimmune GFAP astrocytopathy: Prospective evaluation of 90 patients in 1-â€‹year. <i>Journal of Neuroimmunology</i> , 2018, 321, 157-163.	2.3	136
11	Area postrema syndrome. <i>Neurology</i> , 2018, 91, e1642-e1651.	1.1	129
12	Predictive models in the diagnosis and treatment of autoimmune epilepsy. <i>Epilepsia</i> , 2017, 58, 1181-1189.	5.1	120
13	Expanded Clinical Phenotype, Oncological Associations, and Immunopathologic Insights of Paraneoplastic Kelch-like Protein-11 Encephalitis. <i>JAMA Neurology</i> , 2020, 77, 1420.	9.0	109
14	Varied phenotypes and management of immune checkpoint inhibitor-associated neuropathies. <i>Neurology</i> , 2019, 93, e1093-e1103.	1.1	107
15	Randomized Placebo-â€‹Controlled Trial of Intravenous Immunoglobulin in Autoimmune LGI1/CASPR2 Epilepsy. <i>Annals of Neurology</i> , 2020, 87, 313-323.	5.3	106
16	Neurologic autoimmunity and immune checkpoint inhibitors. <i>Neurology</i> , 2020, 95, e2442-e2452.	1.1	94
17	Consensus disease definitions for neurologic immune-related adverse events of immune checkpoint inhibitors. , 2021, 9, e002890.		87
18	Autoimmune CRMP5 neuropathy phenotype and outcome defined from 105 cases. <i>Neurology</i> , 2018, 90, e103-e110.	1.1	86

#	ARTICLE	IF	CITATIONS
19	Clinical spectrum of high-titre GAD65 antibodies. Journal of Neurology, Neurosurgery and Psychiatry, 2021, 92, 645-654.	1.9	84
20	Autoimmune Epilepsy. Neurotherapeutics, 2019, 16, 685-702.	4.4	83
21	Predictors of neural-specific autoantibodies and immunotherapy response in patients with cognitive dysfunction. Journal of Neuroimmunology, 2018, 323, 62-72.	2.3	68
22	Frequency and characteristics of MRI-negative myelitis associated with MOG autoantibodies. Multiple Sclerosis Journal, 2021, 27, 303-308.	3.0	64
23	LG11 and CASPR2 neurological autoimmunity in children. Annals of Neurology, 2018, 84, 473-480.	5.3	53
24	Paraneoplastic neuronal intermediate filament autoimmunity. Neurology, 2018, 91, e1677-e1689.	1.1	50
25	LG11 antibody encephalitis: acute treatment comparisons and outcome. Journal of Neurology, Neurosurgery and Psychiatry, 2022, 93, 309-315.	1.9	48
26	Botulinum Toxin in Parkinson Disease Tremor. Mayo Clinic Proceedings, 2017, 92, 1359-1367.	3.0	46
27	Antibody Prevalence in Epilepsy and Encephalopathy score: Increased specificity and applicability. Epilepsia, 2019, 60, 367-369.	5.1	43
28	Amphiphysin-IgG autoimmune neuropathy. Neurology, 2019, 93, e1873-e1880.	1.1	41
29	Neural Antibody Testing in Patients with Suspected Autoimmune Encephalitis. Clinical Chemistry, 2020, 66, 1496-1509.	3.2	41
30	Paraneoplastic neurological syndromes: clinical presentations and management. Therapeutic Advances in Neurological Disorders, 2021, 14, 175628642098532.	3.5	41
31	Association of Extension of Cervical Cord Lesion and Area Postrema Syndrome With Neuromyelitis Optica Spectrum Disorder. JAMA Neurology, 2017, 74, 359.	9.0	38
32	Botulinum toxin in essential hand tremor - A randomized double-blind placebo-controlled study with customized injection approach. Parkinsonism and Related Disorders, 2018, 56, 65-69.	2.2	31
33	Brain dysfunction and thyroid antibodies: autoimmune diagnosis and misdiagnosis. Brain Communications, 2021, 3, fcaa233.	3.3	31
34	Autoimmune/Paraneoplastic Encephalitis Antibody Biomarkers: Frequency, Age, and Sex Associations. Mayo Clinic Proceedings, 2022, 97, 547-559.	3.0	29
35	Population-Based Epidemiology Study of Paraneoplastic Neurologic Syndromes. Neurology: Neuroimmunology and Neuroinflammation, 2022, 9, .	6.0	29
36	Leucine Zipper 4 Autoantibody: A Novel Germ Cell Tumor and Paraneoplastic Biomarker. Annals of Neurology, 2021, 89, 1001-1010.	5.3	27

#	ARTICLE	IF	CITATIONS
37	Clinical Course and Features of Seizures Associated With LGI1-Antibody Encephalitis. <i>Neurology</i> , 2021, 97, e1141-e1149.	1.1	27
38	Paraneoplastic Myeloneuropathies. <i>Neurology</i> , 2021, 96, e632-e639.	1.1	26
39	Collapsin Response-Mediator Protein 5â€“Associated Retinitis, Vitritis, and Optic Disc Edema. <i>Ophthalmology</i> , 2020, 127, 221-229.	5.2	25
40	Phenotypic presentations of paraneoplastic neuropathies associated with MAP1B-IgG. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 328-330.	1.9	25
41	CNS Demyelinating Attacks Requiring Ventilatory Support With Myelin Oligodendrocyte Glycoprotein or Aquaporin-4 Antibodies. <i>Neurology</i> , 2021, 97, e1351-e1358.	1.1	25
42	Characterisation of TRIM46 autoantibody-associated paraneoplastic neurological syndrome. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 196-200.	1.9	20
43	Clinical Utility of Antiretinal Antibody Testing. <i>JAMA Ophthalmology</i> , 2021, 139, 658.	2.5	18
44	Clinical Sensitivity, Specificity, and Predictive Value of Neural Antibody Testing for Autoimmune Encephalitis. <i>Journal of applied laboratory medicine, The</i> , 2022, 7, 350-356.	1.3	18
45	Neurofascin-155 Immunoglobulin Subtypes. <i>Neurology</i> , 2021, 97, .	1.1	17
46	Neuronal intermediate filament IgGs in CSF: Autoimmune Axonopathy Biomarkers. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 425-439.	3.7	16
47	Contactin-1 autoimmunity. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e771.	6.0	15
48	Use of diffusion-weighted imaging to distinguish seizure-related change from limbic encephalitis. <i>Journal of Neurology</i> , 2020, 267, 3337-3342.	3.6	15
49	Improving accuracy of myasthenia gravis autoantibody testing by reflex algorithm. <i>Neurology</i> , 2020, 95, e3002-e3011.	1.1	14
50	GFAP IgG associated inflammatory polyneuropathy. <i>Journal of Neuroimmunology</i> , 2020, 343, 577233.	2.3	14
51	Paraneoplastic cochleovestibulopathy: clinical presentations, oncological and serological associations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1181-1185.	1.9	14
52	CASPR2â€“IgGâ€“associated autoimmune seizures. <i>Epilepsia</i> , 2022, 63, 709-722.	5.1	14
53	Musicogenic epilepsy: Expanding the spectrum of glutamic acid decarboxylase 65 neurological autoimmunity. <i>Epilepsia</i> , 2021, 62, e76-e81.	5.1	13
54	Comparison of immune checkpoint inhibitor-related neuropathies among patients with neuroendocrine and non-neuroendocrine tumours. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 112-114.	1.9	13

#	ARTICLE	IF	CITATIONS
55	Botulinum Toxin in Restless Legs Syndromeâ€”A Randomized Double-Blind Placebo-Controlled Crossover Study. <i>Toxins</i> , 2018, 10, 401.	3.4	12
56	B-cellâ€”targeted therapies in relapsing forms of MS. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2017, 4, e405.	6.0	10
57	Identification of Caveolae-Associated Protein 4 Autoantibodies as a Biomarker of Immune-Mediated Rippling Muscle Disease in Adults. <i>JAMA Neurology</i> , 2022, 79, 808.	9.0	10
58	Expanding the Spectrum of Chronic Immune Sensory Polyradiculopathy. <i>Neurology</i> , 2021, 96, e2078-e2089.	1.1	8
59	Teaching Video NeuroImages: Periodic Alternating Nystagmus in Paraneoplastic KLHL11 Rhomboencephalitis. <i>Neurology</i> , 2021, 96, e2668-e2669.	1.1	6
60	Smartphone Apps as a Source of Information About Interventional Radiology. <i>CardioVascular and Interventional Radiology</i> , 2017, 40, 957-958.	2.0	5
61	Paraneoplastic neurological syndrome: an evolving story. <i>Neuro-Oncology Practice</i> , 2021, 8, 362-374.	1.6	5
62	Ondineâ€™s Curse and Trismus in Association With Kelch-like Protein-11 Autoimmunity. <i>JAMA Neurology</i> , 2021, 78, 1016.	9.0	5
63	Pure Motor Onset and IgM-Gammopathy Occurrence in Multifocal Acquired Demyelinating Sensory and Motor Neuropathy. <i>Neurology</i> , 2021, 97, .	1.1	5
64	IgM-gammopathy strongly favours immune treatable MMN and MADSAM over ALS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 324-326.	1.9	4
65	Autoimmune psychosis. <i>Lancet Psychiatry</i> , the, 2020, 7, 122.	7.4	4
66	Paraneoplastic neurological syndrome: growing spectrum and relevance. <i>Neurological Sciences</i> , 2022, 43, 3583-3594.	1.9	4
67	Î²IV-Spectrin Autoantibodies in 2 Individuals With Neuropathy of Possible Paraneoplastic Origin. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	6.0	4
68	Smartphone Applications Providing Information about Stroke: Are We Missing Stroke Risk Computation Preventive Applications?. <i>Journal of Stroke</i> , 2017, 19, 117-117.	3.2	3
69	Clinical Reasoning: A 49-Year-Old Woman With Progressive Numbness and Gait Instability. <i>Neurology</i> , 2021, 97, 342-347.	1.1	2
70	PDCB does not promote CNS autoimmunity in the context of genetic susceptibility but worsens its outcome. <i>Journal of Neuroimmunology</i> , 2018, 323, 53-55.	2.3	1
71	Reply to â€œValue of Onconeural Antibodies in Checkpoint Inhibitorâ€”Related Toxicitiesâ€”. <i>Annals of Neurology</i> , 2020, 88, 200-201.	5.3	1
72	Teaching NeuroImages: Brain and Skin Involvement in Erdheim-Chester Disease. <i>Neurology</i> , 2021, 96, e1590-e1592.	1.1	1

#	ARTICLE	IF	CITATIONS
73	Focal sensory chronic inflammatory demyelinating polyneuropathy (<scp>CIDP</scp>). Muscle and Nerve, 2021, 63, E46-E49.	2.2	1
74	Considering Spastic Paraplegia Type 7 and Adult-Onset Alexander Diseaseâ€™Reply. JAMA Neurology, 2017, 74, 869.	9.0	0
75	003â€™...Autoimmune encephalitis antibody biomarkers: frequency, age and sex associations. , 2021, , .		0